Compare Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Innov-100 0DTE Covered Call Strat ETF vs GeneDx Holdings Corp — how do they compare? Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.5 (market cap $962.24M), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 2.1× Roundhill Innov-100 0DTE Covered Call Strat ETF's market cap, and Roundhill Innov-100 0DTE Covered Call Strat ETF is more actively traded (882,859 versus 734,640). Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Innov-100 0DTE Covered Call Strat ETF for 57 Days and GeneDx Holdings Corp for 19 Days on average.
| QDTE | WGS | |
|---|---|---|
Market Cap | $962.24M | $2.02B |
Volume | 882,859 | 734,640 |
Sector | Income / Options Overlay | Health |
52-Week High | $36.60 | $167.51 |
52-Week Low | $26.85 | $34.51 |
Typical Hold Time | 57 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QDTE (Roundhill Nasdaq-100 0DTE Covered Call Strategy ETF) trades at $29.50, down 1.3% today amid bearish technical signals. The ETF generates weekly income through covered call strategies on Nasdaq-100 components, with recent distributions ranging from $0.11-$0.28. Technical indicators show mixed signals with overall bearish momentum, while fundamental data remains limited for this specialized income-focused product.
The outlook remains cautious as declining volatility pressures distribution yields, with recent payouts suggesting a more sustainable 24-31% annualized yield versus the trailing 43%. Key risks include NAV erosion from return of capital and underperformance in bull markets due to capped upside potential from daily call writing strategies.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
